Literature DB >> 19926820

Thalidomide inhibits inflammatory and angiogenic activation of human intestinal microvascular endothelial cells (HIMEC).

Parvaneh Rafiee1, Daniel J Stein, Victoria M Nelson, Mary F Otterson, Reza Shaker, David G Binion.   

Abstract

The glutamic acid derivative thalidomide is a transcriptional inhibitor of TNF-alpha but is also known to affect human blood vessels, which may underlie its teratogenicity. Thalidomide has been used in the treatment of refractory Crohn's disease (CD), but the therapeutic mechanism is not defined. We examined the effect of thalidomide on primary cultures of human intestinal microvascular endothelial cells (HIMEC), the relevant endothelial cell population in inflammatory bowel disease (IBD), to determine its effect on endothelial activation, leukocyte interaction, and VEGF-induced angiogenesis. HIMEC cultures were pretreated with thalidomide before activation with either TNF-alpha/LPS or VEGF. A low-shear-stress flow adhesion assay with either U-937 or whole blood was used to assess HIMEC activation following TNF-alpha/LPS, and a Wright's stain identified adherent leukocytes. Expression of cell adhesion molecules (E-selectin, intercellular adhesion molecule-1, vascular cell adhesion molecule-1) was assessed using radioimmunoassay. Effects of thalidomide on NF-kappaB activation, cyclooxygenase (COX)-2, and inducible nitric oxide synthase (iNOS) expression in TNF-alpha/LPS-activated HIMEC were determined by RT-PCR and Western blotting. Thalidomide blocked adhesion of both U-937 and whole blood leukocytes by 50% in HIMEC, inhibiting binding of all classes of leukocytes. Thalidomide also blocked NF-kappaB and cell adhesion molecule expression in HIMEC. In marked contrast, thalidomide did not affect either iNOS or COX-2 expression, two key molecules that play a role in the downregulation of HIMEC activation. VEGF-induced HIMEC transmigration, growth, proliferation, tube formation, and Akt phosphorylation were significantly inhibited by thalidomide. In summary, thalidomide exerted a potent effect on HIMEC growth and activation, suggesting that it may also function via an endothelial mechanism in the treatment of CD.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19926820      PMCID: PMC2822501          DOI: 10.1152/ajpgi.00385.2009

Source DB:  PubMed          Journal:  Am J Physiol Gastrointest Liver Physiol        ISSN: 0193-1857            Impact factor:   4.052


  43 in total

Review 1.  Cellular survival: a play in three Akts.

Authors:  S R Datta; A Brunet; M E Greenberg
Journal:  Genes Dev       Date:  1999-11-15       Impact factor: 11.361

Review 2.  Endothelial cell interactions with granulocytes: tethering and signaling molecules.

Authors:  G A Zimmerman; S M Prescott; T M McIntyre
Journal:  Immunol Today       Date:  1992-03

3.  Inhibition of NF-kappa B activity by thalidomide through suppression of IkappaB kinase activity.

Authors:  J A Keifer; D C Guttridge; B P Ashburner; A S Baldwin
Journal:  J Biol Chem       Date:  2001-04-10       Impact factor: 5.157

4.  Thalidomide impairment of trinitrobenzene sulphonic acid-induced colitis in the rat - role of endothelial cell-leukocyte interaction.

Authors:  B Lienenlüke; T Stojanovic; T Fiebig; A Fayyazi; T Germann; M Hecker
Journal:  Br J Pharmacol       Date:  2001-08       Impact factor: 8.739

5.  Vascular endothelial growth factor-stimulated actin reorganization and migration of endothelial cells is regulated via the serine/threonine kinase Akt.

Authors:  M Morales-Ruiz; D Fulton; G Sowa; L R Languino; Y Fujio; K Walsh; W C Sessa
Journal:  Circ Res       Date:  2000-04-28       Impact factor: 17.367

6.  Thalidomide and its analogues inhibit lipopolysaccharide-mediated Iinduction of cyclooxygenase-2.

Authors:  J Fujita; J R Mestre; J B Zeldis; K Subbaramaiah; A J Dannenberg
Journal:  Clin Cancer Res       Date:  2001-11       Impact factor: 12.531

7.  Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis.

Authors:  D Shweiki; A Itin; D Soffer; E Keshet
Journal:  Nature       Date:  1992-10-29       Impact factor: 49.962

8.  Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo.

Authors:  K H Plate; G Breier; H A Weich; W Risau
Journal:  Nature       Date:  1992-10-29       Impact factor: 49.962

9.  Thalidomide is an inhibitor of angiogenesis.

Authors:  R J D'Amato; M S Loughnan; E Flynn; J Folkman
Journal:  Proc Natl Acad Sci U S A       Date:  1994-04-26       Impact factor: 11.205

10.  Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation.

Authors:  A L Moreira; E P Sampaio; A Zmuidzinas; P Frindt; K A Smith; G Kaplan
Journal:  J Exp Med       Date:  1993-06-01       Impact factor: 14.307

View more
  12 in total

1.  The induction strategies administered in the treatment of multiple myeloma exhibit a deleterious effect on the endothelium.

Authors:  Julia Martinez-Sanchez; Marta Palomo; Sergi Torramade-Moix; Ana Belen Moreno-Castaño; Montserrat Rovira; Gonzalo Gutiérrez-García; Francesc Fernández-Avilés; Gines Escolar; Olaf Penack; Laura Rosiñol; Enric Carreras; Maribel Diaz-Ricart
Journal:  Bone Marrow Transplant       Date:  2020-05-13       Impact factor: 5.483

Review 2.  Role of the endothelium in inflammatory bowel diseases.

Authors:  Walter E Cromer; J Michael Mathis; Daniel N Granger; Ganta V Chaitanya; J Steven Alexander
Journal:  World J Gastroenterol       Date:  2011-02-07       Impact factor: 5.742

3.  Anti inflammatory and anti angiogenic effect of black raspberry extract on human esophageal and intestinal microvascular endothelial cells.

Authors:  Rituparna Medda; Orestis Lyros; Jamie L Schmidt; Nebojsa Jovanovic; Linghui Nie; Benjamin J Link; Mary F Otterson; Gary D Stoner; Reza Shaker; Parvaneh Rafiee
Journal:  Microvasc Res       Date:  2014-10-28       Impact factor: 3.514

4.  Thalidomide Inhibits Angiogenesis via Downregulation of VEGF and Angiopoietin-2 in Crohn's Disease.

Authors:  Lin Wang; Shengnan Wang; Aijuan Xue; Jieru Shi; Cuifang Zheng; Ying Huang
Journal:  Inflammation       Date:  2020-11-18       Impact factor: 4.092

5.  Thalidomide plus chemotherapy exhibit enhanced efficacy in the clinical treatment of T-cell non-Hodgkin's lymphoma: A prospective study of 46 cases.

Authors:  Hongyang Wu; Chenchen Zhao; Kangsheng Gu; Yang Jiao; Jiqing Hao; Guoping Sun
Journal:  Mol Clin Oncol       Date:  2014-06-06

Review 6.  Mechanism of immunomodulatory drugs' action in the treatment of multiple myeloma.

Authors:  Xiubao Chang; Yuanxiao Zhu; Changxin Shi; A Keith Stewart
Journal:  Acta Biochim Biophys Sin (Shanghai)       Date:  2013-12-29       Impact factor: 3.848

7.  Nitric oxide rescues thalidomide mediated teratogenicity.

Authors:  Jamila H Siamwala; Vimal Veeriah; M Krishna Priya; Saranya Rajendran; Uttara Saran; Swaraj Sinha; Shunmugam Nagarajan; T Pradeep; Suvro Chatterjee
Journal:  Sci Rep       Date:  2012-09-20       Impact factor: 4.379

8.  Upregulation of miR21 and repression of Grhl3 by leptin mediates sinusoidal endothelial injury in experimental nonalcoholic steatohepatitis.

Authors:  Sahar Pourhoseini; Ratanesh Kumar Seth; Suvarthi Das; Diptadip Dattaroy; Maria B Kadiiska; Guanhua Xie; Gregory A Michelotti; Mitzi Nagarkatti; Anna Mae Diehl; Saurabh Chatterjee
Journal:  PLoS One       Date:  2015-02-06       Impact factor: 3.240

9.  Down-regulation of common NFκB-iNOS pathway by chronic Thalidomide treatment improves Hepatopulmonary Syndrome and Muscle Wasting in rats with Biliary Cirrhosis.

Authors:  Tzu-Hao Li; Pei-Chang Lee; Kuei-Chuan Lee; Yun-Cheng Hsieh; Chang-Youh Tsai; Ying-Ying Yang; Shiang-Fen Huang; Tung-Hu Tsai; Shie-Liang Hsieh; Ming-Chih Hou; Han-Chieh Lin; Shou-Dong Lee
Journal:  Sci Rep       Date:  2016-12-23       Impact factor: 4.379

10.  Angiogenesis enhanced by treatment damage to hepatocellular carcinoma through the release of GDF15.

Authors:  Gang Dong; Qiong-Dan Zheng; Min Ma; Si-Fan Wu; Rui Zhang; Rong-Rong Yao; Yin-Ying Dong; Hui Ma; Dong-Mei Gao; Sheng-Long Ye; Jie-Feng Cui; Zheng-Gang Ren; Rong-Xin Chen
Journal:  Cancer Med       Date:  2018-01-31       Impact factor: 4.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.